Intermittent Theta Burst Stimulation Targets Schizophrenia's Symptoms: Suggest Review
A recent study published in the Indian Journal of Psychiatry in June 2026 highlights intermittent theta burst stimulation (iTBS) as a rapid, non-invasive breakthrough for schizophrenia's notoriously stubborn negative symptoms. Requiring just three to five minutes per session, this targeted neuromodulation safely and effectively delivers substantial clinical relief, offering a promising new frontier in psychiatric care.
Antipsychotics effectively manage positive schizophrenia symptoms, but debilitating negative symptoms remain a significant therapeutic challenge. Given the inconsistent results of conventional repetitive transcranial magnetic stimulation (rTMS), Dr. Nand Kumar and colleagues at AIIMS, New Delhi, systematically reviewed the safety and efficacy of the shorter intermittent theta burst stimulation (iTBS) protocol to address this clinical gap.
Therefore, the researchers reviewed nine randomized controlled trials (n=440; ages 18–60 years) evaluating 10 to 40 sessions of intermittent theta burst stimulation (iTBS). Explicitly excluding non-randomized designs and conventional TMS, the analysis focused on the primary endpoint of negative symptom reduction, alongside secondary measures of cognitive changes, clinical improvement, and treatment tolerability.
Key Clinical Findings of the Review Includes:
• Consistent symptom reduction: Reviewers found that iTBS consistently led to statistically significant and clinically meaningful improvements in negative symptom scores across all evaluated trials.
• Targeted domain impact: Researchers noted specific symptom reductions, with 33% of the analyzed studies showing decreased anhedonia and avolition, and 22% noting improved alogia compared to sham control groups.
• Protocol intensity matters: Investigators observed that stimulation protocols specifically targeting the left dorsolateral prefrontal cortex (L-DLPFC) or cerebellar regions at 80% to 100% of the individual motor threshold delivered the most substantial therapeutic benefits.
• Durable therapeutic effects: Scientists highlighted that the clinical improvements were remarkably sustained long after the intervention concluded, with positive neuroplastic effects persisting robustly at four, twelve, and even twenty-four weeks of follow-up.
• Favorable safety profile: Authors reported that while mild, transient adverse events like localized headaches, nausea, or dizziness occurred slightly more frequently than in sham groups, they were well-tolerated and rarely required treatment discontinuation.
The results suggest that iTBS is a highly viable, well-tolerated, and significantly time-efficient adjunctive intervention capable of delivering meaningful relief for patients suffering from the often refractory negative symptoms of schizophrenia. Furthermore, the sustained improvements seen across various clinical domains emphasize its potential as a targeted, short-duration therapy.
Thus, the review concludes healthcare providers may consider integrating this rapid, noninvasive neuromodulation technique into broader, personalized treatment strategies for patients who demonstrate poor clinical responses or significant side effect burdens to conventional pharmacological therapies.
Although the brief review format lacking formal risk-of-bias assessments and the inherent methodological variability across the included trials present certain analytical limitations, there is a gentle need for future, large-scale, standardized studies to explore how concurrent medications and behavioral training might further enhance these promising neurobiological benefits.
Reference
Kumar N, Hans G, Madiha M, Prasad S, Narnoli S. Safety and efficacy of intermittent theta burst stimulation (iTBS) in schizophrenia with predominant negative symptoms: A brief review. Indian J Psychiatry 2026;68:503-9.
